Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer .
Tarlatamab/ AMGEN . (Byma. .z Bispecific T Cell Engager, BiTE®) in Small Cell Lung Cancer ( DeLLphi-301 ) @JSMO_Official By Dr. Hiroki Izumi.
Tarlatamab Binds DLL3 And CD3 Leading To T Cell Mediated Tumor Lysis.
ORR 23% And PFS 3.7% in Heavily Pretreated SCLC .
